Literature DB >> 12393669

Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival.

Oswaldo Castro1, Mohammed Hoque, Bernice D Brown.   

Abstract

Few results on cardiac catheterization have been published for patients with sickle cell disease (SCD) with pulmonary hypertension (PHTN). Their survival once this complication develops is unknown. We analyzed hemodynamic data in 34 adult patients with SCD at right-sided cardiac catheterization and determined the relationship of PHTN to patient survival. In 20 patients with PHTN the average systolic, diastolic, and mean pulmonary artery pressures were 54.3, 25.2, and 36.0 mm Hg, respectively. For 14 patients with SCD without PHTN these values were 30.3, 11.7, and 17.8 mm Hg, respectively. The mean pulmonary capillary wedge pressure in patients with PHTN was higher than that in patients without PHTN (16.0 versus 10.6 mm Hg; P =.0091) even though echocardiography showed normal left ventricular systolic function. Cardiac output was high (8.6 L/min) for both groups of patients. The median postcatheterization follow-up was 23 months for patients with PHTN and 45 months for those without PHTN. Eleven patients (55%) with PHTN died compared to 3 (21%) patients without PHTN (chi(2) = 3.83; P =.0503). The mean pulmonary artery pressure had a significant inverse relationship with survival (Cox proportional hazards modeling). Each increase of 10 mm Hg in mean pulmonary artery pressure was associated with a 1.7-fold increase in the rate (hazards ratio) of death (95% CI = 1.1-2.7; P =.028). The median survival for patients with PHTN was 25.6 months, whereas for patients without PHTN the survival was still over 70% at the end of the 119-month observation period (P =.044, Breslow-Gehan log-rank test). Our findings suggest that PHTN in patients with SCD shortened their survival.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393669     DOI: 10.1182/blood-2002-03-0948

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  95 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

Review 2.  Managing sickle cell disease.

Authors:  Susan Claster; Elliott P Vichinsky
Journal:  BMJ       Date:  2003-11-15

3.  Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.

Authors:  Robyn J Barst; Kamal K Mubarak; Roberto F Machado; Kenneth I Ataga; Raymond L Benza; Oswaldo Castro; Robert Naeije; Namita Sood; Paul S Swerdlow; Mariana Hildesheim; Mark T Gladwin
Journal:  Br J Haematol       Date:  2010-02-17       Impact factor: 6.998

4.  Hemolysis-associated pulmonary hypertension in thalassemia.

Authors:  Claudia R Morris; Frans A Kuypers; Gregory J Kato; Lisa Lavrisha; Sandra Larkin; Titi Singer; Elliott P Vichinsky
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

5.  Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease.

Authors:  Nalini Raghavachari; Xiuli Xu; Amy Harris; Jose Villagra; Carolea Logun; Jennifer Barb; Michael A Solomon; Anthony F Suffredini; Robert L Danner; Gregory Kato; Peter J Munson; Sidney M Morris; Mark T Gladwin
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

6.  Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease.

Authors:  Vandana Sachdev; Roberto F Machado; Yukitaka Shizukuda; Yesoda N Rao; Stanislav Sidenko; Inez Ernst; Marilyn St Peter; Wynona A Coles; Douglas R Rosing; William C Blackwelder; Oswaldo Castro; Gregory J Kato; Mark T Gladwin
Journal:  J Am Coll Cardiol       Date:  2007-01-16       Impact factor: 24.094

7.  Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis.

Authors:  Catherine J Wu; Mark Gladwin; John Tisdale; Matthew Hsieh; Terence Law; Melinda Biernacki; Shelby Rogers; Xunde Wang; Mark Walters; David Zahrieh; Joseph H Antin; Jerome Ritz; Lakshamanan Krishnamurti
Journal:  Br J Haematol       Date:  2007-11       Impact factor: 6.998

8.  Echocardiographic evaluation of left ventricular diastolic and systolic function in Saudi patients with sickle cell disease.

Authors:  Mohammed Fakhry Abdul-Mohsen
Journal:  J Saudi Heart Assoc       Date:  2012-06-12

9.  Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.

Authors:  Caterina P Minniti; Roberto F Machado; Wynona A Coles; Vandana Sachdev; Mark T Gladwin; Gregory J Kato
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

Review 10.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.